No supplier or customer ties in FLNA's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Nothing on the wire mentions FLNA yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How FLNA has moved on past release days vs its typical ±4.2% day, and how often it closed up. Computed from daily closes — not a forecast.